Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study

Toxicology

Volumn 332, Issue , 2015, Pages 52-66

  Yoon, Miyoung ^a   Kedderis, Gregory L ^b   Yan, Grace Zhixia ^a   Clewell, Harvey J ^a  

^a HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

^b NONE   (United States)

Author keywords

Carbaryl; Cholinesterase inhibition; Hepatocytes; In vitro to in vivo extrapolation; Metabolism; PBPK model

Indexed keywords

CARBARIL; CHOLINESTERASE; CHOLINESTERASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLINESTERASE INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; METABOLIC CLEARANCE; MODEL; NONHUMAN; PHYSIOLOGICALLY BASED PHARMACODYNAMIC MODEL; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; PRIORITY JOURNAL; RAT; TOXICOKINETICS; ADULT; ANIMAL; ANIMAL TESTING ALTERNATIVE; BIOLOGICAL MODEL; BIOTRANSFORMATION; BLOOD; BRAIN; CELL CULTURE; COMPUTER SIMULATION; DRUG EFFECTS; ENZYMOLOGY; ERYTHROCYTE; FEMALE; LIVER CELL; MALE; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; SPECIES DIFFERENCE; SPRAGUE DAWLEY RAT; STATISTICAL MODEL; TOXICITY TESTING; YOUNG ADULT;

RATTUS;

ADULT; ANIMAL TESTING ALTERNATIVES; ANIMALS; BIOTRANSFORMATION; BRAIN; CARBARYL; CELLS, CULTURED; CHOLINESTERASE INHIBITORS; CHOLINESTERASES; COMPUTER SIMULATION; ERYTHROCYTES; FEMALE; HEPATOCYTES; HUMANS; LINEAR MODELS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; RATS, SPRAGUE-DAWLEY; RISK ASSESSMENT; RISK FACTORS; SPECIES SPECIFICITY; TOXICITY TESTS; YOUNG ADULT;

EID: 84930083658     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2014.05.006     Document Type: Article

References (60)

1. Aldunate R., Casar J.C., Brandan E., Inestrosa N.C. Structural and functional organization of synaptic acetylcholinesterase. Brain Res. Brain Res. Rev. 2004, 47:96-104.
2. Andersen M.E., Krewski D. The vision of toxicity testing in the 21st century: moving from discussion to action. Toxicol. Sci. 2010, 117:17-24.
3. Barter Z.E., Bayliss M.K., Beaune P.H., Boobis A.R., Carlile D.J., Edwards R.J., Houston J.B., Lake B.G., Lipscomb J.C., Pelkonen O.R., Tucker G.T., Rostami-Hodjegan A. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr. Drug Metab. 2007, 8:33-45.
4. Barton H.A., Chiu W.A., Woodrow Setzer R., Andersen M.E., Bailer A.J., Bois F.Y., Dewoskin R.S., Hays S., Johanson G., Jones N., Loizou G., Macphail R.C., Portier C.J., Spendiff M., Tan Y.M. Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation. Toxicol. Sci. 2007, 99:395-402.
5. Basketter D.A., Clewell H., Kimber I., Rossi A., Blaauboer B.J., Burrier R., Daneshian M., Eskes C., Goldberg A., Hasiwa N., Hoffman S., Jaworska J., Knudsen T.B., Landsiedel R., Leist M., Locke P., Maxwell G., McKim J., McVey E.A., Ouedraogo G., Patlewicz G., Pelkonen O.R., Roggen E., Rovida C., Ruhdel I., Schwarz M., Schepky A., Schoeters G., Skinner N., Trentz K., Turner M., Vanparys P., Yager J., Zurlo J., Hartung T.A. Roadmap for the development of alternative (non-animal) methods for systemic toxicity testing - t4 report*. ALTEX 2012, 29:3-91.
6. Blaauboer B.J. Biokinetic modeling and in vitro-in vivo extrapolations. J. Toxicol. Environ. Health B: Crit. Rev. 2010, 13:242-252.
7. Brownson C., Watts D.C. The modification of cholinesterase activity by 5,5'-dithiobis-(2-nitrobenzoic acid) included in the coupled spectrophotometric assay. Evidence for a non-catalytic substrate-binding site. Biochem. J. 1973, 131:369-374.
8. Brown R., Delp M., Lindstedt S., Rhomberg L., Beliles R. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 1997, 13407:484.
9. Copeland R.A. Tight Binding Inhibitors, Enzymes 2002, 305-317. John Wiley & Sons Inc., New York.
10. Ellman G.L., Courtney K.D., Andres V., Feather-Stone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7:88-95.
11. Floby E., Johansson J., Hoogstraate J., Hewitt N.J., Hill J., Sohlenius-Sternbeck A.K. Comparison of intrinsic metabolic clearance in fresh and cryopreserved human hepatocytes. Xenobiotica 2009, 39:656-662.
12. Groner E., Ashani Y., Schorer-Apelbaum D., Sterling J., Herzig Y., Weinstock M. The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates. Mol. Pharmacol. 2007, 71:1610-1617.
13. Herr D.W., Mwanza J.C., Lyke D.F., Graff J.E., Moser V.C., Padilla S. Relationship between brain and plasma carbaryl levels and cholinesterase inhibition. Toxicology 2010, 276:172-183.
14. Holm K., McDougall R., Yoon M., Young B., Clewell H., Tornero-Velez R., Goldsmith R., Chang D., Grulke C., Phillips M., Dary C., Tan C. Identifying the sources of uncertainty in the process of reconstructing exposures to carbaryl using exposure-to-dose modeling. Toxicologist 2013, 132:171.
15. Houston J.B., Upshall D.G., Bridges J.W. Pharmacokinetics and metabolism of two carbamate insecticides, carbaryl and landrin, in the rat. Xenobiotica 1975, 5:637-648.
16. Hwang S.W., Schanker L.S. Absorption of carbaryl from the lung and small intestine of the rat. Environ. Res. 1974, 7:206-211.
17. Imai T., Imoto M., Sakamoto H., Hashimoto M. Identification of esterases expressed in Caco-2 cells and effects of their hydrolyzing activity in predicting human intestinal absorption. Drug Metab. Dispos. 2005, 33:1185-1190.
18. Judson R.S., Kavlock R.J., Setzer R.W., Hubal E.A., Martin M.T., Knudsen T.B., Houck K.A., Thomas R.S., Wetmore B.A., Dix D.J. Estimating toxicity-related biological pathway altering doses for high-throughput chemical risk assessment. Chem. Res. Toxicol. 2011, 24:451-462.
19. Kalvass J.C., Maurer T.S. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm. Drug Dispos. 2002, 23:327-338.
20. Kedderis G.L. In vitro to in vivo extrapolation of metabolic rate constants for physiologically based pharmacokinetic models. Toxicokinetics and Risk Assessment 2007, 185-210. Informa Healthcare, New York. J.C. Lipscomb, E.V. Ohanian (Eds.).
21. Kedderis G.L., Argenbright L.S., Miwa G.T. Studies with nitrogen-containing steroids and freshly isolated rat hepatocytes: role of cytochrome P-450 in detoxication. Toxicol. Appl. Pharmacol. 1988, 93:403-412.
22. Kedderis G.L., Held S.D. Prediction of furan pharmacokinetics from hepatocyte studies: comparison of bioactivation and hepatic dosimetry in rats, mice, and humans. Toxicol. Appl. Pharmacol. 1996, 140:124-130.
23. Knaak J.B., Tallant M.J., Kozbelt S.J., Sullivan L.J. The metabolism of carbaryl in man, monkey, pig, and sheep. J. Agric. Food Chem. 1968, 16:465-470.
24. Knudsen T.B., Houck K.A., Sipes N.S., Singh A.V., Judson R.S., Martin M.T., Weissman A., Kleinstreuer N.C., Mortensen H.M., Reif D.M., Rabinowitz J.R., Setzer R.W., Richard A.M., Dix D.J., Kavlock R.J. Activity profiles of 309 ToxCast chemicals evaluated across 292 biochemical targets. Toxicology 2011, 282:1-15.
25. Kousba A.A., Poet T.S., Timchalk C. Characterization of the in vitro kinetic interaction of chlorpyrifos-oxon with rat salivary cholinesterase: a potential biomonitoring matrix. Toxicology 2003, 188:219-232.
26. Kousba A.A., Poet T.S., Timchalk C. Age-related brain cholinesterase inhibition kinetics following in vitro incubation with chlorpyrifos-oxon and diazinon-oxon. Toxicol. sci. 2007, 95:147-155.
27. Lipscomb J.C., Garrett C.M., Snawder J.E. Cytochrome P450-dependent metabolism of trichloroethylene: interindividual differences in humans. Toxicol. Appl. Pharmacol. 1997, 142:311-318.
28. Lipscomb J.C., Poet T.S. In vitro measurements of metabolism for application in pharmacokinetic modeling. Pharmacol. Ther. 2008, 118:82-103.
29. Main A.R. Kinetics of cholinesterase inhibition by organophosphate and carbamate insecticides. Can. Med. Assoc. J. 1969, 100:161-167.
30. Maxwell D.M., Lenz D.E., Groff W.A., Kaminskis A., Froehlich H.L. The effects of blood flow and detoxification on in vivo cholinesterase inhibition by soman in rats. Toxicol. Appl. Pharmacol. 1987, 88:66-76.
31. McCracken N.W., Blain P.G., Williams F.M. Nature and role of xenobiotic metabolizing esterases in rat liver, lung, skin and blood. Biochem. Pharmacol. 1993, 45:31-36.
32. McDaniel K.L., Padilla S., Marshall R.S., Phillips P.M., Podhorniak L., Qian Y., Moser V.C. Comparison of acute neurobehavioral and cholinesterase inhibitory effects of N-methylcarbamates in rat. Toxicol. Sci. 2007, 98:552-560.
33. McGinnity D.F., Soars M.G., Urbanowicz R.A., Riley R.J. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab. Dispos. 2004, 32:1247-1253.
34. Nong A., Tan Y.M., Krolski M.E., Wang J., Lunchick C., Conolly R.B., Clewell H.J. Bayesian calibration of a physiologically based pharmacokinetic/pharmacodynamic model of carbaryl cholinesterase inhibition. J. Toxicol. Environ. Health A 2008, 71:1363-1381.
35. Nostrandt A.C., Duncan J.A., Padilla S. A modified spectrophotometric method appropriate for measuring cholinesterase activity in tissue from carbaryl-treated animals. Fundam. Appl. Toxicol. 1993, 21:196-203.
36. Padilla S. Regulatory and research issues related to cholinesterase inhibition. Toxicology 1995, 102:215-220.
37. Paine M.F., Hart H.L., Ludington S.S., Haining R.L., Rettie A.E., Zeldin D.C. The human intestinal cytochrome P450 "pie". Drug Metab. Dispos. 2006, 34:880-886.
38. Pekas J.C. Gastrointestinal metabolism and transport of pesticidal carbamates. Crit. Rev. Toxicol. 1980, 7:37-101.
39. Roberts W.L., Kim B.H., Rosenberry T.L. Differences in the glycolipid membrane anchors of bovine and human erythrocyte acetylcholinesterases. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:7817-7821.
40. Rodgers T., Leahy D., Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J. Pharm. Sci. 2005, 94:1259-1276.
41. Rodgers T., Rowland M. Physiologically based pharmacokinetic modeling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J. Pharm. Sci. 2006, 95:1238-1257.
42. Rodgers T., Rowland M. Mechanistic approaches to volume of distribution predictions: Understanding the processes. Pharm. Res. 2007, 24:918-933.
43. Rotroff D.M., Wetmore B.A., Dix D.J., Ferguson S.S., Clewell H.J., Houck K.A., Lecluyse E.L., Andersen M.E., Judson R.S., Smith C.M., Sochaski M.A., Kavlock R.J., Boellmann F., Martin M.T., Reif D.M., Wambaugh J.F., Thomas R.S. Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicol. Sci. 2010, 117:348-358.
44. Shen D.D., Kunze K.L., Thummel K.E. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv. Drug Deliv. Rev. 1997, 27:99-127.
45. Shimada T., Tsumura F., Yamazaki H. Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab. Dispos. 1999, 27:1274-1280.
46. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 1994, 270:414-423.
47. Skau K.A. Acetylcholinesterase molecular forms in serum and erythrocytes of laboratory animals. Comp. Biochem. Physiol. C 1985, 80:207-210.
48. Snawder J.E., Lipscomb J.C. Interindividual variance of cytochrome P450 forms in human hepatic microsomes: correlation of individual forms with xenobiotic metabolism and implications in risk assessment. Regul. Toxicol. Pharmacol. 2000, 32:200-209.
49. Sogorb M.A., Vilanova E. Enzymes involved in the detoxification of organophosphorus, carbamate and pyrethroid insecticides through hydrolysis. Toxicol. Lett. 2002, 128:215-228.
50. Sohlenius-Sternbeck A.K. Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements. Toxicol. In Vitro 2006, 20:1582-1586.
51. Tang J., Cao Y., Rose R.L., Hodgson E. In vitro metabolism of carbaryl by human cytochrome P450 and its inhibition by chlorpyrifos. Chem. Biol. Interact. 2002, 141:229-241.
52. Tang J., Chambers J.E. Detoxication of paraoxon by rat liver homogenate and serum carboxylesterases and A-esterases. J. Biochem. Mol. Toxicol. 1999, 13:261-268.
53. Wang C., Murphy S. The role of non-critical binding proteins in the sensitivity of acetylcholin-esterase from different species to diisopropyl fluorophosphate (DFP), in vitro. Life sci. 1982, 31:139-149.
54. Waxman D.J., Lapenson D.P., Aoyama T., Gelboin H.V., Gonzalez F.J., Korzekwa K. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch. Biochem. Biophys. 1991, 290:160-166.
55. Wetmore B.A., Wambaugh J.F., Ferguson S.S., Sochaski M.A., Rotroff D.M., Freeman K., Clewell H.J., Dix D.J., Andersen M.E., Houck K.A., Allen B., Judson R.S., Singh R., Kavlock R.J., Richard A.M., Thomas R.S. Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. Toxicol. Sci. 2012, 125:157-174.
56. Yan G.Z., Brouwer K.L., Pollack G.M., Wang M.Z., Tidwell R.R., Hall J.E., Paine M.F. Mechanisms underlying differences in systemic exposure of structurally similar active metabolites: comparison of two preclinical hepatic models. J. Pharmacol. Exp. Ther. 2011, 337:503-512.
57. Yan G.Z., Generaux C.N., Yoon M., Goldsmith R.B., Tidwell R.R., Hall J.E., Olson C.A., Clewell H.J., Brouwer K.L., Paine M.F. A semiphysiologically based pharmacokinetic modeling approach to predict the dose-exposure relationship of an antiparasitic prodrug/active metabolite pair. Drug Metab. Dispos. 2012, 40:6-17.
58. Yoon M., Campbell J.L., Andersen M.E., Clewell H.J. Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results. Crit. Rev. Toxicol. 2012, 42:633-652.
59. Yoon M., Kedderis G.L., Yang Y., Allen B.C., Yan G.Z., Clewell H.J. Use of in vitro data in PBPK models: an example of in vitro to in vivo extrapolation with carbaryl. Parameters for Pesticide ASQR and PBPK/PD Models for Human Risk Assessment 2012, 323-338. American Chemical Society.
60. Yoon M., Nong A., Clewell H.J., Taylor M.D., Dorman D.C., Andersen M.E. Evaluating placental transfer and tissue concentrations of manganese in the pregnant rat and fetuses after inhalation exposures with a PBPK model. Toxicol. Sci. 2009, 112:44-58.